Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

Conclusions Ivosidenib demonstrated good oral exposure and a long half-life. Robust, persistent plasma 2-HG inhibition was observed in IDH1-mutant cholangiocarcinoma and chondrosarcoma. Ivosidenib 500  mg QD is an appropriate dose irrespective of various intrinsic and extrinsic factors.Trial RegistrationClinicalTrials.gov (NCT02073994).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research